Acumen's sabirnetug Alzheimer's readout nears with amyloid class 3-for-3 in Phase 3
ALTITUDE-AD tests whether an amyloid oligomer-selective antibody can clear the iADRS bar that lecanemab and donanemab have already met, with topline data due within Acumen's 2026 window.
Executive Summary
- Acumen Pharmaceuticals is approaching topline data on sabirnetug in early Alzheimer's disease, testing a mechanism that targets soluble amyloid oligomers rather than the amyloid plaques that approved antibodies in the class already target.
- Two antibodies that bind amyloid plaque broadly have already shown a cognitive and functional benefit against placebo in this population, so the informative result is whether an oligomer-selective approach reaches a comparable effect rather than whether the amyloid hypothesis works at all.
- The trial finished enrollment at its target size and has held a stable enrollment count and Active, not recruiting status for more than a year, which removes execution risk as a factor in when the data arrive.
- A positive result would extend evidence for amyloid-targeting therapy to a second, mechanistically distinct binding approach; a null result would leave the plaque-targeting antibodies as the only validated approach in the class.
The trial
ALTITUDE-AD (NCT06335173) is a randomized, placebo-controlled Phase 2 study of intravenous sabirnetug (ACU193) in 542 patients with mild cognitive impairment or mild dementia due to Alzheimer's disease and confirmed cerebral amyloid accumulation. The trial randomizes patients across three sabirnetug dose arms and one placebo arm, with the primary endpoint measuring change from baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognitive and functional decline. The design also carries 32 secondary endpoints spanning CDR-SB, ADAS-Cog13, amyloid PET, and ARIA safety measures, giving the readout depth beyond the single primary result. NCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why the mechanism differs
Sabirnetug is designed to selectively bind toxic soluble amyloid beta oligomers rather than the aggregated plaque that lecanemab and donanemab target, a distinction Acumen has pursued since its earlier Phase 1 INTERCEPT-AD study. Both lecanemab and donanemab, tested in comparable early Alzheimer's populations, are monoclonal antibodies that also bind amyloid beta and have been advanced into Phase 3 and Phase 4 studies following approval. Sabirnetug shares the same target family and modality as those two direct comparators, so the trial's informative question is whether oligomer selectivity can reproduce the treatment effect those plaque-binding antibodies have already demonstrated, not whether amyloid-directed therapy works in this disease. AcumenAcumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of DirectorsNov 10, 2025
Operational read
The trial's history shows an early registry correction rather than a live enrollment problem: enrollment target dropped from 2,040 to 540 and the primary completion date moved from January 2031 to October 2026 in a single October 2024 update, before the study had begun active recruitment cuts. Since then, the trial has been stable: it moved to Active, not recruiting in December 2024 at its planned end of enrollment, and its enrollment count rose by two patients, from 540 to 542, in October 2025, a change the trial's own operational baseline model classifies as typical and well inside its routine variance band. The primary completion date has stood at October 1, 2026, since that single 2024 correction, with no further slippage recorded. NCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173
Guidance and timing
Acumen's own public guidance has narrowed over time: a March 2025 disclosure pointed to results in the second half of 2026, and a November 2025 disclosure widened that window to the full 2026 calendar year, with the sponsor calling the readout an important catalyst for the program. That guided window remains open through December 31, 2026, and is consistent with the trial's registered primary completion date of October 1, 2026. Acumen+1Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of DirectorsNov 10, 2025A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173
The field
Amyloid-beta oligomer-directed therapy has one industry-sponsored trial active in this indication, sabirnetug's own, making the mechanism itself sparsely represented even as the broader amyloid antibody class is well populated: 112 trials in Alzheimer's disease have used monoclonal antibodies as a modality. The nearest direct comparators by target and modality, lecanemab and donanemab, are both already approved and now being studied in expanded Phase 3 and Phase 4 settings, which sets a working precedent that an amyloid-targeting antibody can move the iADRS-type composite in this population. Sabirnetug's readout is the test of whether that effect generalizes to oligomer-selective binding rather than plaque binding.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.